Home
    • Plans Blog Contact
    Stevanato Group S.p.A. logo

    Stevanato Group S.p.A.

    STVN
    Last price US$21.06
    Market cap US$6.4b
    12M price change -5.05%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    West Pharmaceutical Services IncWST Industry peer Hologic IncHOLX Industry peer HaemoneticsHAE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Stevanato Group S.p.A. Overview

    Industry: Medical Instruments & Supplies

    Sector: Healthcare

    Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for biopharma and healthcare. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for biopharma and healthcare. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include contain Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Stevanato Group S.p.A. into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 06, 2026

    Quarterly result summary

    EX-99.1 Exhibit 99.1 Stevanato Group S.p.A. "Half Year 2026 Financial Results Conference Call" Tuesday, August 04, 2026, 14:30 CET Moderators: Franco Stevanato, Chairman and Chief Executive Officer Marco Dal Lago, Chief Financial Officer Lisa Miles, Chief Com...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    we expect to launch customer validations in the near term.

    Earnings material Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 6-K Aug 06, 2026 Earnings material Earnings release Aug 04, 2026 SEC filing 6-K Aug 04, 2026 SEC filing 6-K Aug 04, 2026 Earnings release Earnings release Aug 04, 2026 SEC filing 6-K Jun 05, 2026 Earnings release Earnings release Jun 05, 2026 SEC filing 6-K May 15, 2026 Transcript exhibit EX-99.1 May 15, 2026 SEC filing 6-K May 07, 2026 Earnings material Earnings release May 07, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Stevanato Group S.p.A. boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Return on Equity

    Score 1.96/5
    Stevanato Group S.p.A. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Stevanato Gr... STVN US$6.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Stevanato Group S.p.A. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Stevanato Gr... STVN US$6.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Leverage

    Score 2.37/5
    Stevanato Group S.p.A. registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Stevanato Gr... STVN US$6.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Stevanato Group S.p.A. logo

    Stevanato Group S.p.A.

    US$21.06

    US$6.4b

    3.90%

    -5.05%